This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) Pharmaceutical composition, ~~characterised in that it contains~~ comprising one or more anticholinergics (1) in combination with one or more TACE inhibitors (2), each optionally in the form of the individual optical isomers, mixtures thereof or racemates and optionally in the form of the pharmacologically acceptable acid addition salts thereof, optionally in the form of the solvates or hydrates and optionally together with a pharmaceutically acceptable excipient.

2. (Currently Amended) Pharmaceutical composition according to claim 1, ~~characterised in that 1~~ wherein (1) is selected from among the tiotropium salts, oxitropium salts or ipratropium salts~~, preferably tiotropium salts~~.

3. (Currently Amended) Pharmaceutical composition according to claim 2, ~~characterised in that 1~~ wherein (1) is present in the form of the chloride, bromide, iodide, methanesulphonate or para-toluenesulphonate~~, preferably in the form of the bromide~~.

4. (Currently Amended) Pharmaceutical composition according to one of claims 1 to 3, ~~characterised in that 2~~ wherein (2) is selected from among SL422, SP057, SC903, SE205, Ro-32-7315, BMS-561392 and PKF 242-484.

5. (Currently Amended) Pharmaceutical composition according to one of claims 1 to 3, ~~characterised in that 2~~ wherein (2) is selected from compounds of formula 2a



2a

wherein

R^1 denotes OH or CH_2OH and

R_2 denotes iso-butyl, phenyl, 4-methyl-phenyl or 4-methoxy-phenyl.

6. (Currently Amended) Pharmaceutical composition according to one of claims 1 to 3, ~~characterised in that 2~~ wherein (2) is selected from the group of compounds consisting of:



,



,



,



,


HOHN
O
H
N
O
O


HO
O
H
N
O
O
N
H


HOHN
O
H
N
O
O
N
H


HOHN
O
H
N
O
O
N
H


























HOHN
O
O
O
H
N


HOHN
O
O
O
H
N


HOHN
O
O
O
H
N
OH


HOHN
O
O
O
H
N























HOHN
O
H
N
O
O
HO

,


HOHN
O
H
N
O
O
O
O

,


HOHN
O
H
N
O
O
OH
O

,


HOHN
O
H
N
O
O
HO



























, and



7. **(Currently Amended)** Pharmaceutical composition according to one of claims 1 to 3, ~~characterised in that 2~~ wherein (2) is selected from the group of compounds consisting of :






















HOHN
O
N
O
OH
O


HOHN
O
N
O
O
O


HO
O
N
O
O
OH
O


HO
N
H
O
N
O
O
OH
O


OMe
OMe
OMe
HO
O
N
H
O
O
O


OMe
OMe
OMe
HO
N
H
O
N
O
O
O



8. (Currently Amended) Pharmaceutical composition according to one of claims 1 to 3, ~~characterized in that 2~~ wherein (2) is selected from the group of compounds consisting of:

- (2*R*,3*S*)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)hexanoic acid [(1*S*)-2,2-dimethyl-1-(1,3-thiazol-2ylcarbamoyl)-1-propyl]amide;
- (2*R*,3*S*)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)-4-methylpentanoic acid [(1*S*,2*S*)-2-methyl-1-(2-pyridylcarbamoyl)-1-butyl]amide;
- (2*R*,3*S*)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)-6,6,6-trifluorohexanoic acid [(1*S*,2*R*)-2-methoxy-1-(1,3-thiazol-2ylcarbamoyl)-1-propyl]amide;
- (2*R*,3*S*)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)pentanoic acid [(1*S*)-2,2-dimethyl-1-(1,3-thiazol-2ylcarbamoyl)-1-propyl]amide;
- (2*R*,3*S*)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)-4-methylpentanoic acid [(1*S*)-3-(2-pyridylcarbonylamino)-1-(1,3-thiazol-2ylcarbamoyl)-1-propyl]amide;
- (2*R*,3*S*)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)-6,6,6-trifluorohexanoic acid [(1*S*,2*S*)-2-methyl-1-(2-pyridylcarbamoyl)-1-butyl]amide;
- (2*R*,3*S*)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)butanoic acid [(1*S*,2*R*)-2-methoxy-1-(1,3-thiazol-2ylcarbamoyl)-1-propyl]amide;
- (2*R*,3*S*)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)butanoic acid [(1*S*)-2,2-dimethyl-1-(1,3-thiazol-2ylcarbamoyl)-1-propyl]amide;
- (2*R*,3*S*)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)-6,6,6-trifluorohexanoic acid [(1*S*,2*S*)-2-methyl-1-(1,3-thiazol-2ylcarbamoyl)-1-butyl]amide.

9. (Currently Amended) Pharmaceutical composition according to one of claims 1 to 3, ~~characterized in that 2~~ wherein (2) is selected from the group of compounds consisting of:

- N-hydroxy-2 (R)-[(4-methoxybenzenesulfonyl)(4-picolyl)amino]-2-(trans-4-propoxycyclohexyl)-acetamide;
- N-hydroxy-2 (R)-[(4-ethoxybenzenesulfonyl)(4-picolyl)amino]-2-(trans-4-propoxycyclohexyl)-acetamide;
- N-hydroxy-2 (R)-[(4-ethoxybenzenesulfonyl)(4-picolyl)amino]-2-(trans-4-ethoxycyclohexyl)-acetamide.

10. (Currently Amended) Pharmaceutical composition according to one of claims 1 to 3, ~~characterized in that 2~~ wherein (2) is selected from the group of compounds consisting of:

- 3-[4-(4-fluorophenoxy)benzenesulfonylamino]azetidine-3-carboxylic acid hydroxyamide;
- 4-[4-(4-fluorophenoxy)benzenesulfonylamino]piperidine-4-carboxylic acid hydroxyamide.

11. (Currently Amended) Pharmaceutical composition according to one of claims 1 to 3, ~~characterized in that 2~~ wherein (2) is selected from the group of compounds consisting of:

- (2R, 3S)-N-hydroxy-3-ethynyl-1-(4-methoxybenzenesulfonyl)-piperidine-2-carboxamide;
- (2R, 3S)-N-hydroxy-1- (4-methoxybenzenesulfonyl)-3- (5-methoxythiophene-2yl-hynyl)-piperidine-2 carboxamide;

- (2R, 3R)-N-hydroxy-1-(4-methoxybenzenesulfonyl)-3-(3-pyridin-3-yl-prop-2-yl)-piperidine2-carboxamide;

- (2S, 3R)-N-hydroxy-4-(4-methoxybenzonesulfonyl)-2-pyridine-3-yl-morpholine-3-carboxamide;

- (2S, 3R)-N-hydroxy-2-hydroxycarbamoyl-4-(4-methoxybenzenesulfonyl)-morpholine-3-carboxamide;

- (2R, 3R)-N-hydroxy-2-hydroxycarbamoyl-4-(4-methoxybenzenesulfonyl)-piperidine-2-carboxamide;

~~- (2R, 3S) N-hydroxy-1-(4-methoxybenzenesulfonyl)-3-(4-phenylpyridine-2-yl) iperidine-2-carboxamide;~~

~~- (2S, 3R) N-hydroxy-1-(4-methoxybenzenesulfonyl)-2-(4-phenylpyridine-2-yl) orpholine-2-carboxamide;~~

- (2R, 3S)-N-hydroxy-1-(4-methoxybenzenesulfonyl)-3-(4-phenylpyridine-2-yl)-piperidine-2-carboxamide;

- (2S, 3R)-N-hydroxy-1-(4-methoxybenzenesulfonyl)-2-(4-phenylpyridine-2-yl)-morpholine-2-carboxamide;

- (2R, 3S)-N-hydroxy-3- (2-chloro-4-fluorophenyl)-1- (4-methoxybenzenesulfonyl)-piperidine-2-carboxamide; and

- (2S, 3R)-N-hydroxy-2-(2-chloro-4-fluorophenyl)-1-(4-methoxybenzenesulfonyl)-piperidine-3-carboxamide.

12. (Currently Amended) Pharmaceutical composition according to one of claims 1 to 3 ~~11, characterised in that the active substances 1 and 2~~ wherein the active substances (1) and (2)

are present either together in a single formulation or in two separate formulations.

13. (Currently Amended) Pharmaceutical composition according to ~~one of claims 1 to 12, characterised in that the weight ratios of 1 to 2 are~~ claim 12, wherein the weight ratio of (1) to (2) is in the range from 1: 1000 to 1: 1~~, preferably from 1: 250 to 1: 2~~.

14. (Currently Amended) Pharmaceutical composition according to ~~one of claims 1 to 13, characterised in that~~ claim 13, wherein a single administration corresponds to a dose of the active substance combination ~~1 and 2~~ (1) and (2) of 1 to 10000µg~~, preferably from 10 to 5000µg~~.

15. (Currently Amended) Pharmaceutical composition according to ~~one of claims 1 to 14, characterised in that it~~ claim 14, which is in the form of a formulation suitable for inhalation.

16. (Currently Amended) Pharmaceutical composition according to claim 15, ~~characterised in that it~~ which is a formulation selected from among inhalable powders, propellant-containing metering aerosols and propellant-free inhalable solutions or suspensions.

17. (Currently Amended) Pharmaceutical composition according to claim 16, ~~characterised in that it~~ which is an inhalable powder which contains ~~1 and 2~~ (1) and (2) in admixture with suitable physiologically acceptable excipients selected from among the monosaccharides, disaccharides, oligo-and polysaccharides, polyalcohols, salts, or mixtures of these excipients with one another.

18. (Currently Amended) Inhalable powder according to claim 17, ~~characterised in that~~ wherein the excipient has a maximum mass mean aerodynamic diameter of up to 250µm~~, preferably between 10 and 150µm~~.

19. (Currently Amended) Capsules, ~~characterised in that they~~ which contain an inhalable powder according to claim 17 ~~or 18~~.

20. (Currently Amended) Pharmaceutical composition according to claim 16, ~~characterised in that it~~ which is an inhalable powder which contains only the active substances ~~1 and 2~~ (1) and (2) as its ingredients.

21. (Currently Amended) Pharmaceutical composition according to claim 16, ~~characterised in that it~~ which is a propellant-containing inhalable aerosol which contains ~~1 and 2~~ (1) and (2) in dissolved or dispersed form.

22. (Currently Amended) Propellant-containing inhalable aerosol according to claim 21, ~~characterised in that it~~ which contains, as propellant gas, hydrocarbons ~~such as n-propane, n-butane or isobutane~~ or halohydrocarbons ~~such as chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane~~.

23. (Currently Amended) Propellant-containing inhalable aerosol according to claim 22~~, characterised in that~~ wherein the propellant gas is TG134a, TG227 or a mixture thereof.

24. (Currently Amended) Pharmaceutical composition according to claim 16, ~~characterised in that it~~ which is a propellant-free inhalable solution or suspension which contains water, ethanol or a mixture of water and ethanol as solvent.

25. (Currently Amended) Inhalable solution or suspension according to claim 24, ~~characterised in that~~ wherein the pH is 2-7~~, preferably 2-5~~.

26. – 28. (Canceled)

29. (New) A method for administering an inhalable powder contained in a capsule according to claim 19, wherein the capsule is provided in an inhaler and the inhaler is operated to release the inhalable powder for administration.

30. (New) A method for administering an inhalable powder of claim 18 contained in a capsule, wherein the capsule is provided in an inhaler and the inhaler is operated to release the inhalable powder for administration.

31. (New) A method for administering an inhalable solution according to claim 24, which comprises nebulizing the inhalable solution in an inhaler for administration.

32. (New) A method for administering an inhalable solution according to claim 25, which comprises nebulizing the inhalable solution in an inhaler for administration.

33. (New) The method of claim 31, wherein the inhaler is an inhaler according to WO 91/14468 or an inhaler as described in Figures 6a and 6b of WO 97/12687.

34. (New) A method for treating an inflammatory or obstructive disease of the respiratory tract which comprises administering to a patient a composition according to one of claims 1 to 3.

35. (New) Pharmaceutical composition according to claim 1, wherein (1) is selected from among the tiotropium salts.

36. (New) Pharmaceutical composition according to claim 2, wherein (1) is present in the form of a bromide.